{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:26:08Z","timestamp":1775136368338,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40123-026-01355-8","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:53:24Z","timestamp":1773510804000},"page":"1485-1498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Feasibility of the Exchange Procedure for the Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-7405","authenticated-orcid":false,"given":"John P.","family":"Berdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-8307","authenticated-orcid":false,"given":"Robert P.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-2720","authenticated-orcid":false,"suffix":"Jr.","given":"Steven R.","family":"Sarkisian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Applegate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jay","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7971-5292","authenticated-orcid":false,"given":"Angela C.","family":"Kothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3577-3096","authenticated-orcid":false,"given":"Tomas","family":"Navratil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"11","key":"1355_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"Y-C Tham","year":"2014","unstructured":"Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology"},{"key":"1355_CR2","doi-asserted-by":"crossref","unstructured":"Mangione CM on behalf of the US Preventive Services Task Force. Screening for primary open-angle glaucoma. US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(20):1992\u20137.","DOI":"10.1001\/jama.2022.7013"},{"key":"1355_CR3","doi-asserted-by":"crossref","unstructured":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429\u201340.","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"1355_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"1355_CR5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"1355_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2008.08.051","volume":"116","author":"DC Musch","year":"2009","unstructured":"Musch DC, Gillespie BW, Lichter PR, et al. Visual field progression in the collaborative initial glaucoma treatment study the impact of treatment and other baseline factors. Ophthalmology. 2009;116:200\u20137.","journal-title":"Ophthalmology"},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295\u2013304.","journal-title":"Lancet"},{"issue":"4","key":"1355_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/112067210901900409","volume":"19","author":"GCM Rossi","year":"2009","unstructured":"Rossi GCM, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"1355_CR9","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.2147\/OPTH.S388886","volume":"16","author":"G Li","year":"2022","unstructured":"Li G, Akpek EK, Ahmad S. Glaucoma and ocular surface disease: more than meets the eye. Clin Ophthalmol. 2022;16:3641\u20139.","journal-title":"Clin Ophthalmol"},{"key":"1355_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393\u20138.","journal-title":"J Glaucoma"},{"key":"1355_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/IJG.0b013e31820bd2e1","volume":"21","author":"R Gupta","year":"2012","unstructured":"Gupta R, Patil B, Shah BM, et al. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21:189\u201392.","journal-title":"J Glaucoma"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3129\/i08-076","volume":"43","author":"R Kholdebarin","year":"2008","unstructured":"Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454\u201361.","journal-title":"Can J Ophthalmol"},{"key":"1355_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0002-9394(14)71282-6","volume":"116","author":"WC Stewart","year":"1993","unstructured":"Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116:176\u201381.","journal-title":"Am J Ophthalmol"},{"key":"1355_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5301\/EJO.2010.6112","volume":"21","author":"GC Rossi","year":"2011","unstructured":"Rossi GC, Pasinetti GM, Scudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21:410\u20134.","journal-title":"Eur J Ophthalmol"},{"key":"1355_CR15","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","volume":"118","author":"B Sleath","year":"2011","unstructured":"Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398\u2013402.","journal-title":"Ophthalmology"},{"issue":"4","key":"1355_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, et al. The association between medication adherence and visual field progression in the Collaborative Initial Glaucoma Treatment Study (CIGTS). Ophthalmology. 2020;127(4):477\u201383.","journal-title":"Ophthalmology"},{"issue":"3","key":"1355_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/IJG.0000000000001982","volume":"31","author":"AP Rajanala","year":"2022","unstructured":"Rajanala AP, Prager AJ, Park MS, Tanna AP. Association of the effectiveness of eye drop self-instillation and glaucoma progression. J Glaucoma. 2022;31(3):156\u20139.","journal-title":"J Glaucoma"},{"issue":"1","key":"1355_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18240\/ijo.2021.01.21","volume":"14","author":"NP Kesav","year":"2021","unstructured":"Kesav NP, Young CEC, Ertel MK, et al. Sustained-release drug delivery systems for the treatment of glaucoma. Int J Ophthalmol. 2021;14(1):148\u201359.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"1355_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/jcm12010151","volume":"12","author":"B Cvenkel","year":"2023","unstructured":"Cvenkel B, Kolko M. Devices and treatments to address low adherence in glaucoma patients: a narrative review. J Clin Med. 2023;12(1):151\u201371.","journal-title":"J Clin Med"},{"key":"1355_CR20","unstructured":"Glaukos Corporation. Press release: Glaukos announces US FDA approval of NDA supplement allowing for re-administration of iDose\u00ae TR. 28 January 2026. https:\/\/investors.glaukos.com\/news\/news-details\/2026\/Glaukos-Announces-US-FDA-Approval-of-NDA-Supplement-Allowing-for-Re-Administration-of-iDose-TR\/default.aspx."},{"key":"1355_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40265-023-01973-7","volume":"84","author":"JP Berdahl","year":"2024","unstructured":"Berdahl JP, Sarkisian SR, Ang RE, et al. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. Drugs. 2024;84:83\u201397.","journal-title":"Drugs"},{"issue":"3","key":"1355_CR22","first-page":"779","volume":"38","author":"WM Bourne","year":"1997","unstructured":"Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci. 1997;38(3):779\u201382.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1355_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ajo.2019.07.016","volume":"208","author":"JH Lass","year":"2019","unstructured":"Lass JH, Benetz BA, He J, et al. Corneal endothelial cell loss and morphometric changes 5 years after phacoemulsification with or without CyPass micro-stent. Am J Ophthalmol. 2019;208:211\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1355_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ophtha.2022.02.021","volume":"129","author":"IIK Ahmed","year":"2022","unstructured":"Ahmed IIK, De Francesco T, Rhee D, et al. Long-term outcomes from the HORIZON randomized trial for a Schlemm\u2019s canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742\u201351.","journal-title":"Ophthalmology"},{"issue":"12","key":"1355_CR25","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","volume":"127","author":"FA Medeiros","year":"2020","unstructured":"Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627\u201341.","journal-title":"Ophthalmology"},{"key":"1355_CR26","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","volume":"81","author":"J Bacharach","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81:2017\u201333.","journal-title":"Drugs"},{"key":"1355_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40123-025-01130-1","volume":"14","author":"G Szekely","year":"2025","unstructured":"Szekely G, Voskanyan LA, Stephens KG, et al. Aqueous humor concentrations of travoprost free acid and residual drug in explanted implants from patients administered a travoprost intracameral implant. Ophthalmol Ther. 2025;14:989\u20131003.","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01355-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:42:11Z","timestamp":1775133731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01355-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01355-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have made the following disclosures: John P. Berdahl, Robert P. Lehmann, Jason J. Jones, and Steven R. Sarkisian received financial support from Glaukos Corporation. David Applegate, L. Jay Katz, Angela C. Kothe, and Tomas Navratil are employees of Glaukos Corporation and may have received stock and\/or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was registered at Clinicaltrials.gov (NCT04615403) and was conducted in accordance with the tenets of the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practices. Institutional Review Board\/ Ethics Committee approval (Western Institutional Review Board, Puyallup, Washington for all sites in the USA [approval number 20202929], and St. Cabrini Medical Center \u2013 Asian Eye Institute Ethics Review Committee, Makati City, Philippines for the single site in the Philippines [approval number 2020\u2013035]) was obtained prior to undertaking any study related procedures, and all subjects provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}